Double down for a double win

The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are define...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 18; no. 8; pp. 2124 - 2126
Main Author Huang, Pearl S
Format Journal Article
LanguageEnglish
Published United States 15.04.2012
Subjects
Female
Humans
Male
MAP Kinase Signaling System - drug effects
Neoplasms - drug therapy
Online AccessGet full text

Cover

More Information
Summary:The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are defined by genetic lesions, are showing promising responses to this approach.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-12-0461